Current international trends in the treatment of multiple sclerosis in children-Impact of the COVID-19 pandemic.
COVID-19
Disease modifying therapy
MS
Paediatric
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
02
07
2021
revised:
06
09
2021
accepted:
23
09
2021
pubmed:
9
10
2021
medline:
17
12
2021
entrez:
8
10
2021
Statut:
ppublish
Résumé
Only recently has the first disease-modifying therapy been approved for children with multiple sclerosis (MS) and practice patterns including substantial off-label use have evolved. Understanding attitudes towards treatment of paediatric MS and whether this has changed due to the ongoing COVID-19 pandemic is vital to guide future therapeutic trials and for developing guidelines that reflect practice. We performed an online survey within the International Paediatric Multiple Sclerosis Study Group between July and September 2020. The survey was sent to 130 members from 25 countries and consisted of five sections: demographic data, treatment, disease modifying therapies and COVID-19, outcome and three patient cases. The survey was completed by 66 members (51%), both paediatric neurologists and adult neurologists. Fingolimod and β-interferons were the most frequently used disease-modifying therapies, especially among paediatric neurologists. Almost a third (31%) of respondents had altered their prescribing practice due to COVID-19, in particular at the beginning of the pandemic. The survey results indicate a tendency of moving from the traditional escalation therapy starting with injectables towards an early start with newer, highly effective disease modifying therapies. The COVID-19 pandemic only slightly affected prescribing patterns and treatment choices in paediatric MS.
Sections du résumé
BACKGROUND
BACKGROUND
Only recently has the first disease-modifying therapy been approved for children with multiple sclerosis (MS) and practice patterns including substantial off-label use have evolved. Understanding attitudes towards treatment of paediatric MS and whether this has changed due to the ongoing COVID-19 pandemic is vital to guide future therapeutic trials and for developing guidelines that reflect practice.
METHODS
METHODS
We performed an online survey within the International Paediatric Multiple Sclerosis Study Group between July and September 2020. The survey was sent to 130 members from 25 countries and consisted of five sections: demographic data, treatment, disease modifying therapies and COVID-19, outcome and three patient cases.
RESULTS
RESULTS
The survey was completed by 66 members (51%), both paediatric neurologists and adult neurologists. Fingolimod and β-interferons were the most frequently used disease-modifying therapies, especially among paediatric neurologists. Almost a third (31%) of respondents had altered their prescribing practice due to COVID-19, in particular at the beginning of the pandemic.
CONCLUSIONS
CONCLUSIONS
The survey results indicate a tendency of moving from the traditional escalation therapy starting with injectables towards an early start with newer, highly effective disease modifying therapies. The COVID-19 pandemic only slightly affected prescribing patterns and treatment choices in paediatric MS.
Identifiants
pubmed: 34624643
pii: S2211-0348(21)00544-7
doi: 10.1016/j.msard.2021.103277
pmc: PMC8474759
pii:
doi:
Substances chimiques
Fingolimod Hydrochloride
G926EC510T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103277Informations de copyright
Copyright © 2021. Published by Elsevier B.V.
Références
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
Mult Scler. 2012 Jan;18(1):116-27
pubmed: 22146610
N Engl J Med. 2018 Sep 13;379(11):1017-1027
pubmed: 30207920
Mult Scler. 2019 Jun;25(7):927-936
pubmed: 30945587
Bone Marrow Transplant. 1997 Oct;20(8):631-8
pubmed: 9383225
Mult Scler. 2006 Dec;12(6):814-23
pubmed: 17263012
Neurology. 2014 Oct 14;83(16):1432-8
pubmed: 25217060
Neurotherapeutics. 2017 Oct;14(4):985-998
pubmed: 28895071
Neurology. 2020 Sep 29;95(13):e1844-e1853
pubmed: 32690790
Bone Marrow Transplant. 2017 Aug;52(8):1133-1137
pubmed: 28319075
Mult Scler. 2021 Nov;27(13):1970-1976
pubmed: 32633605
J Neurol. 2020 Dec;267(12):3467-3475
pubmed: 32638107
Neurology. 2020 Jun 2;94(22):949-952
pubmed: 32241953
Ann Neurol. 2020 Jul;88(1):42-55
pubmed: 32267005
Neurol Neuroimmunol Neuroinflamm. 2020 Jul 9;7(5):
pubmed: 32646885
Eur J Paediatr Neurol. 2019 Nov;23(6):792-800
pubmed: 31551133
Neurol Neuroimmunol Neuroinflamm. 2021 May 21;8(4):
pubmed: 34021056
Neurology. 2006 Feb 28;66(4):472-6
pubmed: 16505297
Neurology. 2016 Aug 30;87(9 Suppl 2):S97-S102
pubmed: 27572869
Mult Scler. 2022 Jan;28(1):132-138
pubmed: 33764197
Neuropediatrics. 2003 Jun;34(3):120-6
pubmed: 12910434
Mult Scler Relat Disord. 2019 Feb;28:276-282
pubmed: 30639830
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
Neurology. 2014 Dec 2;83(23):2140-6
pubmed: 25378667
Neurology. 2018 Nov 6;91(19):e1778-e1787
pubmed: 30333163